Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;18(1):2355150.
doi: 10.1080/19336950.2024.2355150. Epub 2024 May 19.

Ionotropic purinergic receptor 7 (P2X7) channel structure and pharmacology provides insight regarding non-nucleotide agonism

Affiliations
Review

Ionotropic purinergic receptor 7 (P2X7) channel structure and pharmacology provides insight regarding non-nucleotide agonism

Rua'a Al-Aqtash et al. Channels (Austin). 2024 Dec.

Abstract

P2X7 is a member of the Ionotropic Purinergic Receptor (P2X) family. The P2X family of receptors is composed of seven (P2X1-7), ligand-gated, nonselective cation channels. Changes in P2X expression have been reported in multiple disease models. P2Xs have large complex extracellular domains that function as receptors for a variety of ligands, including endogenous and synthetic agonists and antagonists. ATP is the canonical agonist. ATP affinity ranges from nanomolar to micromolar for most P2XRs, but P2X7 has uniquely poor ATP affinity. In many physiological settings, it may be difficult to achieve the millimolar extracellular ATP concentrations needed for P2X7 channel activation; however, channel function is implicated in pain sensation, immune cell function, cardiovascular disease, cancer, and osteoporosis. Multiple high-resolution P2X7 structures have been solved in apo-, ATP-, and antagonist-bound states. P2X7 structural data reveal distinct allosteric and orthosteric antagonist-binding sites. Both allosteric and orthosteric P2X7 antagonists are well documented to inhibit ATP-evoked channel current. However, a growing body of evidence supports P2X7 activation by non-nucleotide agonists, including extracellular histone proteins and human cathelicidin-derived peptides (LL-37). Interestingly, P2X7 non-nucleotide agonism is not inhibited by allosteric antagonists, but is inhibited by orthosteric antagonists. Herein, we review P2X7 function with a focus on the efficacy of available pharmacology on P2X7 channel current activation by non-nucleotide agonists in effort to understand agonist/antagonist efficacy, and consider the impact of these data on the current understanding of P2X7 in physiology and disease given these limitations of P2X7-selective antagonists and incomplete knockout mouse models.

Keywords: P2X7; P2XR; extracellular histones; non-nucleotide agonism.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Four sets of images of high-resolution crystal structures of the P2X7 ion channel with top-down and side-on views showing the channel in nine different ligand-bound states.
Figure 1.
Functionally important binding sites aligned on full-length P2X7 structure. (a) full-length structures of rat P2X7 in the putative closed (Apo, 6U9V) and open (ATP, 6U9W) states. (b,c) top-down (top) and side-on (bottom) views of the three, inter-subunit, ATP binding sites (B, ATP), and single orthosteric binding sites (B) and allosteric binding sites (C). (d) side-on view of a single P2X7 channel subunit (6U9V) to highlight locations of relevant binding sites and functionally important features.

Similar articles

References

    1. Burnstock G. Do some nerve cells release more than one transmitter? Neuroscience. 1976. Aug;1(4):239–17. doi: 10.1016/0306-4522(76)90054-3 - DOI - PubMed
    1. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev. 1998. Sep;50(3):413–492. - PubMed
    1. Khakh BS, North RA. P2X receptors as cell-surface ATP sensors in health and disease. Nature. 2006. Aug 3;442(7102):527–532. doi: 10.1038/nature04886 - DOI - PubMed
    1. North RA. P2X receptors. Philos Trans R Soc Lond B Biol Sci. 2016. Aug 5;371(1700). - PMC - PubMed
    1. Burnstock G. The therapeutic potential of purinergic signalling. Biochem Pharmacol. 2018. May;151:157–165. doi: 10.1016/j.bcp.2017.07.016 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources